Provectus Biopharmaceuticals, Inc.
Income Statement
| Line Item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $57.5K | $278.6K | $14.3K | $109.7K | $255.0K | $238.1K | $121.1K | $69.7K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $880.8K | $402.7K | $608.2K | $414.0K | $472.9K | $555.5K | $415.8K | $350.8K |
| SG&A Expense | $977.4K | $973.9K | $1.7M | $651.5K | $576.9K | $129.8K | $310.0K | $433.1K |
| Operating Income | $-1.8M | $-1.1M | $-2.3M | $-955.7K | $-794.9K | $-447.3K | $-604.7K | $-714.1K |
| Operating Margin | -3,132.8% | -394.1% | -16,289.0% | -870.9% | -311.7% | -187.9% | -499.3% | -1,024.1% |
| Interest Expense | $2.0K | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-1.8M | $-1.1M | $-2.4M | $-1.0M | $-846.8K | $-504.0K | $-663.4K | $-775.8K |
| Net Margin | -3,156.6% | -409.2% | -16,517.7% | -924.3% | -332.1% | -211.7% | -547.8% | -1,112.6% |
| EPS (Basic) | $0.00 | $0.00 | $-0.01 | $0.00 | $0.00 | $0.00 | $-0.01 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $-0.01 | $0.00 | $0.00 | $0.00 | $-0.01 | $0.00 |
| Shares Outstanding (Basic) | 420.3M | 420.3M | 419.8M | 419.9M | 419.5M | 419.5M | 419.5M | 419.5M |
| Shares Outstanding (Diluted) | 420.3M | 420.3M | 419.8M | 419.9M | 419.5M | 419.5M | 419.5M | 419.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |